1250 ET - Zimmer Biomet Holdings' deal for Paragon 28 comes with little integration risk and could accelerate growth, says Jefferies in a research note. The medical technology company agreed to acquire all outstanding shares of Paragon, a medical-device maker that focuses exclusively on the foot and ankle orthopedic segment, for $13 a share. "We are fans of the deal and view this as good portfolio management and a reasonable price," says Taylor. Shares of Paragon rise 8.5% to $13.03, while Zimmer ticks down 0.6% to $111.15. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
January 29, 2025 12:50 ET (17:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.